gw590735
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2003 (NCT00169559)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
PPARA agonist
Not in pipeline, development discontinued?
Chemistry & pharmacology
Loading structure…
SMILES
Cc1nc(-c2ccc(C(F)(F)F)cc2)sc1C(=O)NCc1ccc(OC(C)(C)C(=O)O)cc1- Mol. weight
- 478.49 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL219586 ↗
Also known as
- 2-methyl-2-(4-(((4-methyl-2-(4-trifluoromethylphenyl)-thiazol-5-ylcarbonyl)amino)methyl)phenoxy)propionic acid
- gw590735
- gw590735
- gw590735
- gw590735
- gw 590735
- gw-590735
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00169559 | Phase 2 | Nov 1, 2003 | GlaxoSmithKline |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2003 |
1 organizations
Page 1 / 1